Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Aim To explore changes in body weight and cardiometabolic risk factors after treatment
withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …

Importance Weight loss improves cardiometabolic risk factors in people with overweight or
obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective …

Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …